In vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form - DB1965 - against Trypanosoma cruzi infection

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  da Silva, Cristiane França ^a   Batista, Denise da Gama Jaen ^a   Oliveira, Gabriel Melo ^a   de Souza, Elen Mello ^a   Hammer, Erica Ripoll ^a   da Silva, Patricia Bernardino ^a   Daliry, Anissa ^a   Araujo, Julianna Siciliano ^a   Britto, Constança ^a   Rodrigues, Ana Carolina Mondaine ^a   Liu, Zongying ^b   Farahat, Abdelbasset A ^b   Kumar, Arvind ^b   Boykin, David W ^b   Soeiro, Maria de Nazaré Correia ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; DB 1831; DB 1965; UNCLASSIFIED DRUG; AMIDE; AMIDINE; ANTIPROTOZOAL AGENT; DB1831; MESYLIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAMMAL CELL; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARASITE CLEARANCE; SURVIVAL RATE; TRYPOMASTIGOTE; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; GROWTH, DEVELOPMENT AND AGING; MORTALITY; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; TRYPANOSOMA CRUZI;

ANIMALIA; MAMMALIA; PROTOZOA; TRYPANOSOMA CRUZI;

AMIDES; AMIDINES; ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; CHAGAS DISEASE; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; MESYLATES; MICE; MODELS, BIOLOGICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PYRIMIDINES; TREATMENT OUTCOME; TRYPANOSOMA CRUZI;

EID: 84856116592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030356     Document Type: Article

References (31)

1. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, et al. (2010) Chagas disease: changes in knowledge and management. Lancet Infect Dis 10 (8): 556-70.
2. Soeiro MdeN, de Castro SL, (2011) Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies. Open Med Chem J 5: 21-30.
3. Romanha AJ, Castro SL, Soeiro MdeN, Lannes-Vieira J, Ribeiro I, et al. (2010) In vitro and in vivo experimental models for drug screening and evelopment for Chagas disease. Mem Inst Oswaldo Cruz 105: 233-8.
4. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I, (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A 105: 5022-7.
5. Moreno M, D'ávila DA, Silva MN, Galvão LM, Macedo AM, et al. (2010) Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem Inst Oswaldo Cruz 105: 918-24.
6. Soeiro MN, de Castro SL, (2009) Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opin Ther Targets 13: 105-121.
7. Clayton J, (2010) Chagas disease: pushing through the pipeline. Nature 465: S12-5.
8. Werbovetz K, (2006) Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Investig Drugs 7: 147-57.
9. Soeiro MN, De Souza EM, Stephens CE, Boykin DW, (2005) Aromatic diamidines as antiparasitic agents. Expert Opin Investig Drugs 14: 957-72.
10. Stephens CE, Brun R, Salem MM, Werbovetz KA, Tanious F, et al. (2003) The activity of diguanidino and 'reversed' diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani. Bioorg Med Chem Lett 13: 2065-9.
11. Batista DdaG, Batista MM, de Oliveira GM, do Amaral PB, Lannes-Vieira J, et al. (2010) Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment. Antimicrob Agents Chemother 54: 2940-52.
12. Silva CF, Batista MM, Mota RA, De Souza EM, Stephens CE, et al. (2007) Activity of "reversed" diamidines against Trypanosoma cruzi in vitro. Biochem Pharmacol 73: 1939-46.
13. Silva CF, Meuser MB, De Souza EM, Meirelles MN, Stephens CE, et al. (2007) Cellular effects of reversed amidines on Trypanosoma cruzi. Antimicrob Agents Chemother 51: 3803-9.
14. Da Silva CF, Junqueira A, Lima MM, Romanha AJ, Sales Junior PA, et al. (2011) In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi. J Antimicrob Chemother 66: 1295-7.
15. Batista DGJ, Batista MM, Oliveira GM, Britto CC, Rodrigues ACM, et al. (2011) Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi in vivo. Plos One 6 (7): e22155.
16. Wang MZ, Zhu X, Srivastava A, Liu Q, Sweat JM, et al. (2010) Novel arylimidamides for treatment of visceral leishmaniasis. Antimicrob Agents Chemother 54: 2507-16.
17. Meirelles MN, Araujo-Jorge TC, Miranda CF, De Souza W, Barbosa HS, (1986) Interaction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. Eur J Cell Biol 41: 198-206.
18. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
19. de Souza EM, Oliveira GM, Boykin DW, Kumar A, Hu Q, et al. (2006) Trypanocidal activity of the phenyl-substituted analogue of furamidine DB569 against Trypanosoma cruzi infection in vivo. J Antimicrob Chemother 58: 610-4.
20. de Oliveira GM, da Silva TM, Batista WS, Franco M, Schor N, (2009) Acute Trypanosoma cruzi experimental infection induced renal ischemic/reperfusion lesion in mice. Parasitol Res 106: 111-20.
21. da Silva CF, Batista MM, Batista DGJ, De Souza EM, da Silva PB, et al. (2008) In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi. Antimicrob Agents Chemother 52: 3307-14.
22. Britto C, Cardoso MA, Wincker P, Morel CM, (1993) A simple protocol for the physical cleavage of Trypanosoma cruzi kinetoplast DNA present in blood samples and its use in polymerase chain reaction (PCR)-based diagnosis of chronic Chagas disease. Mem Inst Oswaldo Cruz 88: 171-2.
23. Wincker P, Britto C, Pereira JB, Cardoso MA, Oelemann W, et al. (1994) Use of a simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood samples from chronic chagasic patients in a rural endemic area. Am J Trop Med Hyg 51: 771-7.
24. Gascón J, Albajar P, Cañas E, Flores M, Prat I, et al. (2007) Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev Esp Cardiol 60: 285-293.
25. Cortes HC, Muller N, Boykin D, Stephens CE, Hemphill A, (2011) In vitro effects of arylimidamides against Besnoitia besnoiti infection in Vero cells. Parasitology 138: 583-92.
26. Richard JV, Werbovetz KA, (2010) New antileishmanial candidates and lead compounds. Curr Opin Chem Biol 14: 447-55.
27. De Souza EM, Lansiaux A, Bailly C, Wilson WD, Hu Q, et al. (2004) Phenyl substitution of furamidine markedly potentiates its anti-parasitic activity against Trypanosoma cruzi and Leishmania amazonensis. Biochem Pharmacol 68: 593-600.
28. Caldas IS, Talvani A, Caldas S, Carneiro CM, de Lana M, et al. (2008) Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res 103: 413-21.
29. Wainwright M, (2010) Dyes, trypanosomiasis and DNA: a historical and critical review. Biotech Histochem 85: 341-54.
30. De Castro S, Batista DGJ, Batista MM, Batista W, Daliry A, et al. (2011) Experimental chemotherapy for Chagas' disease: a morphological, biochemical and proteomic overview of Trypanosoma cruzi targets. Molecular Biology International In press.
31. Salomão K, de Souza EM, Carvalho SA, da Silva EF, Fraga CA, et al. (2010) In vitro and in vivo activities of 1,3,4-thiadiazole-2-arylhydrazone derivatives of megazol against Trypanosoma cruzi. Antimicrob Agents Chemother 54 (5): 2023-31.